Skip to main content
. 2019 Oct 22;10:2493. doi: 10.3389/fimmu.2019.02493

Figure 1.

Figure 1

NKT-like cells are decreased in treated CML patients. Heparinized fresh whole blood samples were stained with extracellular antibodies and analyzed by multiparametric flow cytometry. (A) Gating strategy to identify NKT-like population. From left to right, gate on lymphocytes, followed by single cells selection and NKT-like identification (CD3+CD56+). (B) CML vs. HD—Relative and absolute frequency of lymphocytes and NKT-like cells in CML patients (n = 48) and HD (n = 40). (C) TKI generation—Relative and absolute frequency of lymphocytes and NKT-like cells in 1st (n = 36) and 2nd TKI generation CML patients (n = 12). (D) Molecular Response—Relative and absolute frequency of lymphocytes and NKT-like cells in CML patients that achieved deep molecular response (DMR; n = 38) and with no DMR (No-DMR; n = 10). Mann Whitney U-test was used for statistical analysis and the charts represent the mean ± standard deviation for HD (n = 40) and CML (n = 48) group. HD, Healthy donors; CML, Chronic Myeloid Leukemia patients; TKI, Tyrosine Kinase Inhibitor; 1st gen. TKI, 1st generation TKI CML patients; 2nd gen. TKI, 2nd generation TKI CML patients; DMR, deep molecular response; no-DMR, without deep molecular response; p-value <0.05*, <0.01**, <0.001***, or <0.0001****.